23 July 2020  
EMA/CHMP/385004/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
NovoThirteen 
catridecacog 
On 23 July 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product 
NovoThirteen. The marketing authorisation holder for this medicinal product is Novo Nordisk A/S. 
The CHMP adopted an extension to the existing indication as follows:2  
Long term prophylaxisctic treatment of bleeding in patients with congenital factor XIII A-subunit 
deficiency. Treatment of breakthrough bleeding episodes during regular prophylaxis. 
NovoThirteen can be used for all age groups.  
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR) and will be available in all official European Union languages after a decision on this change to the 
marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text shown in bold; removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
